Sunrise in melanoma management: Time to focus on melanoma burden in Asia

Asia-Pacific Journal of Clinical Oncology

Volumn 13, Issue 6, 2017, Pages 423-427

  Chang, John Wen Cheng ^a   Guo, Jun ^b   Hung, Chia Yen ^c   Lu, Si ^b   Shin, Sang Joon ^d   Quek, Richard ^e   Ying, Anthony ^f   Ho, Gwo Fuang ^g   Nguyen, Huu Sau ^h   Dhabhar, Boman ⁱ   Sriuranpong, Virote ^j   Tiambeng, Maria Luisa ^k   Prayogo, Nugroho ^l   Yamazaki, Naoya ^m  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d Yonsei University College of Medicine   (South Korea)

^e DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^f Ying Chi Ho Anthony Clinic   (Hong Kong)

^g UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^h National Hospital of Dermatology and Venereology   (Viet Nam)

ⁱ FORTIS HOSPITAL   (India)

^j KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^k Cardinal Santos Cancer Center   (Philippines)

^l Dharmais Cancer Hospital National Cancer Center   (Indonesia)

^m NATIONAL CANCER CENTER HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR;

ADVANCED CANCER; ARTICLE; ASIA; AWARENESS; BRAF GENE; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; DISEASE BURDEN; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; ETHNIC DIFFERENCE; GENE; GENE MUTATION; HUMAN; KIT GENE; MELANOMA; MOLECULARLY TARGETED THERAPY; MORTALITY RISK; NRAS GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; SUN EXPOSURE; SURVIVAL RATE;

EID: 85013677371     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12670     Document Type: Article

References (43)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide. Lyon, France: International Agency for Research on Cancer; 2013. Available from http://globocan.iarc.fr/Default.aspx. Accessed on July 21, 2016.
2. Chang JWC, Yeh KY, Wang CH, et al. Malignant melanoma in Taiwan: A prognostic study of 181 cases. Melanoma Res. 2004;14:537–541.
3. Fujisawa Y, Fujimoto M. Statistics for malignant melanoma in Japan: A nationwide survey from 2005 to 2013. Skin Cancer (Japan). 2014;29:189–194.
4. Chi Z, Li S, Sheng X, et al. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases. BMC Cancer. 2011;11:85.
5. Altekruse SF, Kosary CL, Krapcho M, et al. SEER cancer statistics review, 1975–2007. Bethesda, MD: National Cancer Institute; 2009. Available from http://seer.cancer.gov/csr/1975_2007/. Accessed on July 21, 2016.
6. Dickson PV, Gershenwald JE. Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am. 2011;20:1–17.
7. American Cancer Society. Cancer facts & figures 2015. Atlanta, GA: American Cancer Society; 2015. Available from http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf. Accessed on July 21, 2016.
8. Bellew S, Del Rosso JQ, Kim GK. Skin cancer in Asians: Part 2: Melanoma. J Clin Aesthet Dermatol. 2009;2:34–36.
9. Roh MR, Kim J, Chung KY. Treatment and outcomes of melanoma in acral location in Korean patients. Yonsei Med J. 2010;51:562–568.
10. Lee HY, Chay WY, Tang M, et al. Melanoma: Differences between Asian and Caucasian patients. Ann Acad Med Singapore. 2012;41:17–20.
11. Ishihara K, Saida T, Otsuka F, et al. Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol. 2008;13:33–41.
12. Erdei E, Torres SM. A new understanding in the epidemiology of melanoma. Expert Rev Anticancer Ther. 2010;10:1811–1823.
13. Cormier JN, Xing Y, Ding M, et al. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med. 2006;166:1907–1914.
14. Shoo BA, Kashani-Sabet M. Melanoma arising in African-, Asian-, Latino- and Native-American populations. Semin Cutan Med Surg. 2009;28:96–102.
15. Bradford PT, Goldstein AM, McMaster ML, et al. Acral lentiginous melanoma: Incidence and survival patterns in the United States, 1986–2005. Arch Dermatol. 2009;145:427–434.
16. Chang JW. Cutaneous melanoma: Taiwan experience and literature review. Chang Gung Med J. 2010;33:602–612.
17. Green A, McCredie M, MacKie R, et al. A case–control study of melanomas of the soles and palms (Australia and Scotland). Cancer Causes Control. 1999;10:21–25.
18. Jung HJ, Kweon SS, Lee JB, et al. A clinicopathologic analysis of 177 acral melanomas in Koreans: Relevance of spreading pattern and physical stress. JAMA Dermatol. 2013;149:1281–1288.
19. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: An analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134:1527–1534.
20. Platz A, Egyhazi S, Ringborg U, et al. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol. 2008;1:395–405.
21. Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85.
22. Shinozaki M, Fujimoto A, Morton DL, et al. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res. 2004;10:1753–1757.
23. Sheen YS, Liao YH, Liau JY, et al. Prevalence of BRAF and NRAS mutations in cutaneous melanoma patients in Taiwan. J Formos Med Assoc. 2016;115:121–127.
24. Si L, Kong Y, Xu X, et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer. 2012;48:94–100.
25. Jin SA, Chun SM, Choi YD, et al. BRAF mutations and KIT aberrations and their clinicopathological correlation in 202 Korean melanomas. J Invest Dermatol. 2013;133:579–582.
26. Lee HW, Song KH, Hong JW, et al. Frequency of BRAF mutation and clinical relevance for primary melanomas. Korean J Pathol. 2012;46:246–252.
27. Hong JW, Lee S, Kim DC, et al. Prognostic and clinicopathologic associations of BRAF mutation in primary acral lentiginous melanoma in Korean patients: A preliminary study. Ann Dermatol. 2014;26:195–202.
28. Sakaizawa K, Ashida A, Uchiyama A, et al. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients. J Dermatol Sci. 2015;80:33–37.
29. Yamazaki N, Tanaka R, Tsutsumida A, et al. BRAF V600 mutations and pathological features in Japanese melanoma patients. Melanoma Res. 2015;25:9–14.
30. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340–4346.
31. Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008;14:6821–6827.
32. Tzen CY, Wu YH, Tzen CY. Characterization of KIT mutation in melanoma. Dermatol Sin. 2014;32:7–12.
33. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29:2904–2909.
34. Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31:3182–3190.
35. Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: An emerging therapeutic target in melanoma. Clin Cancer Res. 2013;19:5320–5328.
36. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
37. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–2526.
38. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889–1894.
39. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–330.
40. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–384.
41. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532.
42. Dummer R, Hauschild A, Lindenblatt N, et al. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v126–v132.
43. Deeks ED. Nivolumab: A review of its use in patients with malignant melanoma. Drugs. 2014;74:1233–1239.